A distinct innate immune signature marks progression from mild to severe COVID-19

DOI: 10.1016/j.xcrm.2020.100166
Cell Reports Medicine, 2021, 2, 100166.

#	Paper	IF	Citations
86	A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene. *Brain*, **2021**,	11.2	14
85	In depth analysis of patients with severe SARS-CoV-2 in sub-Saharan Africa demonstrates distinct clinical and immunological profiles. **2021**,		2
84	Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. **2021**,		3
83	Letter in reply to the letter to the editor of Harte JV and Mykytiv V with the title "A panhaemocytometric approach to COVID-19: a retrospective study on the importance of monocyte and neutrophil population data". *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, e173-e174	5.9	1
82	Blunted Fas signaling favors RIPK1-driven neutrophil necroptosis in critically ill COVID-19 patients.		1
81	Genetic variability associated with OAS1 expression in myeloid cells increases the risk of Alzheimer□ disease and severe COVID-19 outcomes.		
80	Systemic Tissue and Cellular Disruption from SARS-CoV-2 Infection revealed in COVID-19 Autopsies and Spatial Omics Tissue Maps. **2021**,		3
79	Endothelial cell, myeloid, and adaptive immune responses in SARS-CoV-2 infection. *FASEB Journal*, **2021**, 35, e21577	0.9	6
78	Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection. *Cell Reports Medicine*, **2021**, 2, 100291	18	4
77	The Coronavirus Network Explorer: mining a large-scale knowledge graph for effects of SARS-CoV-2 on host cell function. *BMC Bioinformatics*, **2021**, 22, 229	3.6	3
76	African Americans and European Americans exhibit distinct gene expression patterns across tissues and tumors associated with immunologic functions and environmental exposures. *Scientific Reports* , **2021**, 11, 9905	4.9	6
75	Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**, 76, 2866-2881	9.3	15
74	Leukocytes Parameters, CRP, and Ferritin in Iranian Patients with COVID-19 Infection; A Cross-sectional Study. *Iranian Journal of Medical Microbiology*, **2021**, 15, 361-368	0.4	1
73	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. *Microorganisms*, **2021**, 9,	4.9	2
72	Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. *Frontiers in Immunology*, **2021**, 12, 650465	8.4	10
71	Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets. *Frontiers in Immunology*, **2021**, 12, 680134	8.4	18
70	Severe Clinical Worsening in COVID-19 and Potential Mechanisms of Immune-Enhanced Disease. *Frontiers in Medicine*, **2021**, 8, 637642	4.9	4

69	A functionally distinct neutrophil landscape in severe COVID-19 reveals opportunities for adjunctive therapies.		
68	Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. *Nature Communications*, **2021**, 12, 3554	17.4	3
67	Identification of COVID-19 and Dengue Host Factor Interaction Networks Based on Integrative Bioinformatics Analyses. *Frontiers in Immunology*, **2021**, 12, 707287	8.4	3
66	CD169 Defines Activated CD14 Monocytes With Enhanced CD8 T Cell Activation Capacity. *Frontiers in Immunology*, **2021**, 12, 697840	8.4	6
65	Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. *Cell Host and Microbe*, **2021**, 29, 1052-1062	23.4	54
64	Deep learning identifies antigenic determinants of severe SARS-CoV-2 infection within T-cell repertoires. *Scientific Reports*, **2021**, 11, 14275	4.9	3
63	CD8+ T cell signature in acute SARS-CoV-2 infection identifies memory precursors.		
62	Innate and Adaptive Immune Assessment at Admission to Predict Clinical Outcome in COVID-19 Patients. *Biomedicines*, **2021**, 9,	4.8	2
61	Putative Role of Vitamin D for COVID-19 Vaccination. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
60	IMMUNOLOGICAL INSIGHTS INTO THE THERAPEUTIC ROLES OF CD24Fc AGAINST SEVERE COVID-19. **2021**,		1
59	Spatially Resolved Immunometabolism to Understand Infectious Disease Progression. *Frontiers in Microbiology*, **2021**, 12, 709728	5.7	1
58	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. *Frontiers in Immunology*, **2021**, 12, 719023	8.4	7
57	Single-cell analysis of COVID-19, sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive signatures in monocytes. *Cell Reports*, **2021**, 37, 109793	10.6	2
56	Further Findings Concerning Endothelial Damage in COVID-19 Patients. *Biomolecules*, **2021**, 11,	5.9	0
55	Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2 subjects. *Cell Research*, **2021**, 31, 1148-1162	24.7	4
54	A Multi-Modal Toolkit for Studying Neutrophils in Cancer and Beyond. *Cancers*, **2021**, 13,	6.6	1
53	Mass Cytometry and Artificial Intelligence Define CD169 as a Marker of SARS-CoV2-Induced Acute Respiratory Distress Syndrome. *SSRN Electronic Journal*,	1	
52	Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology.. *Journal of Hematology and Oncology*, **2022**, 15, 5	22.4	2

51	Immune-guided therapy of COVID-19.. *Cancer Immunology Research*, **2022**,	12.5	2
50	Autoantibodies in COVID-19 correlate with anti-viral humoral responses and distinct immune signatures.		0
49	Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19.. *PLoS Pathogens*, **2022**, 18, e1010176	7.6	2
48	Regulatory T-cells are central hubs for age-, sex- and severity-associated cellular networks during COVID-19.		1
47	A functionally distinct neutrophil landscape in severe COVID-19 reveals opportunities for adjunctive therapies.. *JCI Insight*, **2021**,	9.9	4
46	Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome.. *Nature Communications*, **2022**, 13, 446	17.4	14
45	System-wide transcriptome damage and tissue identity loss in COVID-19 patients.. *Cell Reports Medicine*, **2022**, 3, 100522	18	2
44	Prognostic peripheral blood biomarkers at ICU admission predict COVID-19 clinical outcomes.		0
43	Modelling policy combinations of vaccination and transmission suppression of SARS-CoV-2 in Rio de Janeiro, Brazil.. *Infectious Disease Modelling*, **2022**, 7, 231-242	15.7	
42	Metabolic reprograming shapes neutrophil functions in severe COVID-19. *European Journal of Immunology*, **2021**,	6.1	7
41	Signature of long-lived memory CD8 T cells in acute SARS-CoV-2 infection. *Nature*, **2021**,	50.4	10
40	Transcriptomic Profiles Reveal Downregulation of Low-Density Lipoprotein Particle Receptor Pathway Activity in Patients Surviving Severe COVID-19.. *Cells*, **2021**, 10,	7.9	0
39	Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.. *International Journal of Biological Sciences*, **2022**, 18, 1865-1877	11.2	0
38	Robust differential composition and variability analysis for multisample cell omics.		
37	How Is Mass Spectrometry Tackling the COVID-19 Pandemic?. **2022**, 2,		0
36	Molecular and Clinical Prognostic Biomarkers of COVID-19 Severity and Persistence.. *Pathogens*, **2022**, 11,	4.5	3
35	Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures.. *Allergy: European Journal of Allergy and Clinical Immunology*, **2022**,	9.3	3
34	Poly(I:C) Enhances Mesenchymal Stem Cell Control of Myeloid Cells From COVID-19 Patients.. *IScience*, **2022**, 104188	6.1	0

33	Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression.. *Heliyon*, **2022**, 8, e09230	3.6	1
32	High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients.. *Pathogens*, **2021**, 10,	4.5	0
31	Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19.. *Frontiers in Immunology*, **2022**, 13, 821730	8.4	1
30	The SARS-CoV-2 receptor-binding domain facilitates neutrophil transepithelial migration and nanoparticle uptake in the mice airways.		
29	T HELPER CELL SUBSETS AND THEIR TARGET CELLS IN ACUTE COVID-19. *Russian Journal of Infection and Immunity*,	0.4	0
28	T cell recovery and evidence of persistent immune activation 12 months after severe COVID-19.. *Allergy: European Journal of Allergy and Clinical Immunology*, **2022**,	9.3	0
27	Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course.		0
26	Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview. *Viruses*, **2022**, 14, 1082	6.2	2
25	Neutrophils in COVID-19: Not Innocent Bystanders. *Frontiers in Immunology*, **2022**, 13,	8.4	7
24	Molecular and cellular immune features of aged patients with severe COVID-19 pneumonia. *Communications Biology*, **2022**, 5,	6.7	2
23	Autoimmunity and SARS-CoV-2 infection: unraveling the link in neurological disorders. *European Journal of Immunology*,	6.1	0
22	A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce. **2022**, 12,		0
21	Cellular heterogeneity in disease severity and clinical outcome: Granular understanding of immune response is key. 13,		
20	Integration of protein context improves protein-based COVID-19 patient stratification. **2022**, 19,		
19	Two Years into the COVID-19 Pandemic: Lessons Learned.		4
18	Respiratory and systemic monocytes, dendritic cells and myeloid-derived suppressor cells in COVID-19: Implications for disease severity.		1
17	A rapid, easy, and scalable whole blood monocyte CD169 assay for outpatient screening during SARS-CoV-2 outbreak, and potentially other emerging disease outbreaks. **2022**, 10, 205031212211154		0
16	Mechanisms regulating neutrophil responses in immunity, allergy, and autoimmunity.		0

15	Myeloid CD169/Siglec1: An immunoregulatory biomarker in viral disease. 9,	1
14	Altered Surface Expression of Insulin-Degrading Enzyme on Monocytes and Lymphocytes from COVID-19 Patients Both at Diagnosis and after Hospital Discharge. **2022**, 23, 11070	0
13	Genome-wide Mendelian randomization and single-cell RNA sequencing analyses identify the causal effects of COVID-19 on 41 cytokines.	0
12	Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. 13,	2
11	Immune Profiling and Multiplexed Label-Free Detection of 2D MXenes by Mass Cytometry and High-Dimensional Imaging. 2205154	1
10	Phenotypic alteration of low-density granulocytes in people with pulmonary post-acute sequalae of SARS-CoV-2 infection.	0
9	Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits. 13,	1
8	IMMUNE PROFILES TO DISTINGUISH HOSPITALIZED VERSUS AMBULATORY COVID-19 CASES IN OLDER PATIENTS. **2022**, 105608	0
7	Prognostic peripheral blood biomarkers at ICU admission predict COVID-19 clinical outcomes. 13,	0
6	Dengue & COVID-19: A Comparison and the Challenges at Hand. **2022**,	0
5	Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors. **2022**, 20,	1
4	The Association of Low CD4 Expression on Monocytes and Low CD8+ T-Cell Count at Hospital Admission Predicts the Need for Mechanical Ventilation in Patients With COVID-19 Pneumonia: A Prospective Monocentric Cohort Study. **2022**, 4, e0810	0
3	Phenotypic alteration of low-density granulocytes in people with pulmonary post-acute sequalae of SARS-CoV-2 infection. 13,	0
2	Proteomic understanding of SARS-CoV-2 infection and COVID-19: Biological, diagnostic, and therapeutic perspectives. **2023**, 61-85	0
1	Kinetics of CD169, HLA-DR, and CD64 expression as predictive biomarkers of SARS-CoV2 outcome. **2023**, 3,	0